Viking Therapeutics (VKTX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-150.9M
Net Income
-110.0M
Balance Sheet Metrics
Total Assets
908.3M
Total Liabilities
28.0M
Shareholders Equity
880.3M
Debt to Equity
0.03
Cash Flow Metrics
Operating Cash Flow
-76.7M
Free Cash Flow
-87.8M
Revenue & Profitability Trend
Viking Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 150.9M | 100.8M | 70.4M | 55.7M | 42.7M |
| Operating Income | -150.9M | -100.8M | -70.4M | -55.7M | -42.7M |
| Pre-tax Income | -110.0M | -85.9M | -68.9M | -55.0M | -39.5M |
| Income Tax | - | - | - | - | - |
| Net Income | -110.0M | -85.9M | -68.9M | -55.0M | -39.5M |
| EPS (Diluted) | - | -$0.91 | -$0.90 | -$0.71 | -$0.54 |
Income Statement Trend
Viking Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 907.2M | 367.2M | 167.0M | 210.5M | 256.1M |
| Non-Current Assets | 1.1M | 1.3M | 1.5M | 134.0K | 398.0K |
| Total Assets | 908.3M | 368.5M | 168.5M | 210.7M | 256.5M |
| Liabilities | |||||
| Current Liabilities | 27.4M | 19.1M | 21.9M | 8.8M | 12.1M |
| Non-Current Liabilities | 630.0K | 936.0K | 1.3M | 0 | 29.0K |
| Total Liabilities | 28.0M | 20.1M | 23.2M | 8.8M | 12.2M |
| Equity | |||||
| Total Shareholders Equity | 880.3M | 348.4M | 145.3M | 201.9M | 244.3M |
Balance Sheet Composition
Viking Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -110.0M | -85.9M | -68.9M | -55.0M | -39.5M |
| Operating Cash Flow | -76.7M | -69.8M | -52.3M | -50.3M | -29.4M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Investing Cash Flow | -553.4M | -179.1M | 54.8M | 38.0M | 41.6M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 601.7M | 264.6M | 3.3M | -753.0K | -322.0K |
| Free Cash Flow | -87.8M | -73.4M | -48.4M | -47.6M | -21.8M |
Cash Flow Trend
Viking Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-17.71
Price to Book
3.55
PEG Ratio
-17.71
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-14.40%
Return on Assets
-11.74%
Financial Health
Current Ratio
44.25
Debt to Equity
0.12
Beta
0.64
Per Share Data
EPS (TTM)
-$1.16
Book Value per Share
$7.54
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| vktx | 3.0B | - | 3.55 | -14.40% | 0.00% | 0.12 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.